Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Theravance Biopharma ( (TBPH) ) is now available.
On August 15, 2025, Theravance Biopharma and Mylan entered into a Settlement Agreement with Cipla to resolve ongoing patent litigation over YUPELRI® inhalation solution. The agreement allows Cipla to manufacture and market a generic version of YUPELRI® in the U.S. starting April 23, 2039, pending review by U.S. authorities, while litigation continues against Mankind Pharma Ltd.
The most recent analyst rating on (TBPH) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Theravance Biopharma stock, see the TBPH Stock Forecast page.
Spark’s Take on TBPH Stock
According to Spark, TipRanks’ AI Analyst, TBPH is a Neutral.
Theravance Biopharma’s overall stock score reflects a mix of financial stabilization and strategic achievements, particularly highlighted by the strong earnings call performance. The technical analysis indicates positive momentum, but the high P/E ratio suggests overvaluation. The company’s financial performance shows improvement, yet profitability challenges persist.
To see Spark’s full report on TBPH stock, click here.
More about Theravance Biopharma
Theravance Biopharma is a pharmaceutical company focused on the development and commercialization of respiratory medicines, with YUPELRI® (revefenacin) inhalation solution being one of its primary products.
Average Trading Volume: 297,533
Technical Sentiment Signal: Buy
Current Market Cap: $685.4M
For detailed information about TBPH stock, go to TipRanks’ Stock Analysis page.